Zenas BioPharma Inc ZBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Zenas BioPharma to Host Virtual R&D Event
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $28.26
- Day Range
- $28.03–29.93
- 52-Week Range
- $13.50–44.31
- Bid/Ask
- $29.28 / $29.50
- Shares Outstanding
- 67.82M
- Market Cap
- $1.99B
- Volume/Avg
- 196,526 / 657,620
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 152.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
- Website
- https://www.zenasbio.com
Valuation
Metric | ZBIO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.02 |
Price/Sales | 152.44 |
Price/Cash Flow | — |
Price/Earnings
ZBIO
Financial Strength
Metric | ZBIO |
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 9.42 |
Interest Coverage | −15.57 |
Quick Ratio
ZBIO
Profitability
Metric | ZBIO |
|---|---|
Return on Assets (Normalized) | −60.63% |
Return on Equity (Normalized) | −139.08% |
Return on Invested Capital (Normalized) | −92.17% |
Return on Assets
ZBIO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|N$?t##R | LOCK|f^tMV | $139B | |||
| Moderna Inc MRNA | LOCK|SVV@v$> | LOCK|?@L | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|t$CrvKk | LOCK|XZY@ | $94B | |||
| argenx SE ADR ARGX | LOCK|^>K>%r | LOCK|^gy | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#dhT#> | LOCK|^v | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|J#n&G^^N | LOCK|G^>f | $30B | |||
| Incyte Corp INCY | LOCK|fv?$>V | LOCK|%L | $24B | |||
| BioNTech SE ADR BNTX | LOCK|HJ@Y^T | LOCK|!?L | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|p<HQ!q | LOCK|%z#d@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|q<D<Y!B | LOCK|!^ | $15B |
United States